Diagnostic Tests Maker Veracyte's Q2 Is 'All-Around Very Good Quarter': Analysts Maintain Bullish ViewBenzinga • 08/07/24
Wall Street Analysts See a 37.09% Upside in Veracyte (VCYT): Can the Stock Really Move This High?Zacks Investment Research • 06/21/24
Veracyte (VCYT) Up 8.4% Since Last Earnings Report: Can It Continue?Zacks Investment Research • 06/06/24
Veracyte Announces that New Afirma GRID Data Suggest Prognostic Ability of Molecular Testing for Thyroid TumorsBusiness Wire • 06/03/24
Wall Street Analysts Think Veracyte (VCYT) Could Surge 39.07%: Read This Before Placing a BetZacks Investment Research • 05/29/24
Veracyte (VCYT) Crossed Above the 50-Day Moving Average: What That Means for InvestorsZacks Investment Research • 05/29/24
Veracyte Announces Multiple Afirma GRID Presentations at ENDO 2024, Previewing the Future of Molecular Testing in Thyroid Nodules and CancerBusiness Wire • 05/22/24
Wall Street Analysts Believe Veracyte (VCYT) Could Rally 39.59%: Here's is How to TradeZacks Investment Research • 05/13/24
14 Studies Presented at AUA 2024 Show Decipher Tests' Ability to Help Personalize Care for Prostate and Bladder Cancer Patients and Advance Disease UnderstandingBusiness Wire • 05/06/24